How to Find Undervalued Stocks

A stock is undervalued when its price is lower than a reasonable estimate of the underlying business’s worth. There are two ways to make that estimate, and serious investors use both.

• Below intrinsic value. Intrinsic value is what the business is worth based on the cash it can generate over time, estimated with a discounted-cash-flow (DCF) model. If the market price is well below that estimate, the stock may be undervalued in absolute terms.
• Below peers or its own history. Relative valuation compares a stock’s multiples (P/E, P/B, EV/EBITDA) against similar companies or against where the same stock has traded in the past. A bank at 8 times earnings when its peers trade at 12 is cheap on a relative basis.

The crucial point is that both are estimates, not facts. Intrinsic value depends entirely on the assumptions you feed the model, and relative value depends on the peer set you choose. So “undervalued” is always a judgment about the gap between price and an estimate of worth, never a settled number. That is also why two careful investors can look at the same stock and disagree.

No single metric proves a stock is cheap, which is why investors read several together and weigh the caveats. Each one answers a slightly different question, and each one can mislead on its own. Here is what the common measures mean and where they trip people up.

• P/E and forward P/E. The price you pay per dollar of earnings, trailing or estimated. Low is cheaper, but a low P/E can simply mean the market expects profits to fall.
• P/B (price to book). Price against net assets. Most meaningful for banks, insurers, and other asset-heavy businesses, and close to useless for asset-light software companies.
• PEG (P/E to growth). Adjusts the P/E for expected growth. A reading near or below 1 suggests you are not overpaying for the growth, assuming the growth shows up.
• EV/EBITDA. Enterprise value over operating earnings, which puts companies with different debt loads on the same footing. A favorite for comparing across capital structures.
• Free-cash-flow yield. The cash the business actually throws off, divided by its market value. A higher yield can mean you are paying less for real cash rather than accounting earnings.
• DCF / intrinsic value. The most complete view and the most assumption-dependent. Treat the output as a range, not a precise figure, because small input changes swing it widely.

The table below is a quick reference for the same metrics, including the caveat that matters most for each one.

Use these together, never alone. The caveat column is the part most cheap-stock screens ignore, and it is where value traps hide.

The single biggest mistake in value investing is buying a value trap: a stock that screens as cheap but is cheap because the business is in trouble. The low multiple is not a market error; it is the market correctly pricing declining earnings, a shrinking market, heavy debt, weak management, or a structural threat. The price looks like a discount and then keeps falling.

A few patterns separate a genuine bargain from a trap, and they are qualitative as much as quantitative.

• Are earnings stable or declining? A low trailing P/E on falling earnings often means a much higher forward P/E. Cyclical businesses look cheapest right before their profits roll over.
• Is the balance sheet sound? Heavy debt can make EV/EBITDA look fine while leaving little room for error. Check leverage, interest coverage, and cash.
• Is the business durable? A cheap stock in a structurally declining industry can stay cheap or get cheaper. A temporary stumble in a strong franchise is a different situation.
• Does the cash flow back up the earnings? Profits that never turn into free cash flow are a warning sign that the accounting earnings may not be real economic value.

This is why screening is only the first step. A metric tells you a stock is cheap; only the research tells you whether it deserves to be.

Screening is a funnel: start broad on the numbers, then narrow with judgment. A repeatable process looks like this, and none of it is a recommendation, just the framework value investors commonly use.

• Set valuation filters. For example, a forward P/E below the market, a PEG near 1, or an EV/EBITDA below the company’s peers. This produces a candidate list, nothing more.
• Add quality filters. Layer on positive and stable earnings, a healthy free-cash-flow yield, and manageable debt, so the list is cheap-and-sound rather than just cheap.
• Compare to history and peers. Check whether each name is cheap versus its own past valuation and versus similar companies, not just versus the whole market.
• Read the business. For every survivor, ask why it is cheap. Temporary problem or permanent decline? This is the step that separates bargains from value traps.
• Estimate a value range. A rough DCF or a peer multiple gives you an idea of upside and a margin of safety, so you are buying at a discount to your own estimate, not at any price.

These are screening examples, not picks. Each is a large, well-covered company that has at times traded below the broad market on common valuation measures, included to show how the metrics map onto real businesses. Valuations change constantly, so treat every name as a starting point for your own research and verify current figures. Nothing here is a recommendation, and a cheap multiple is never a guarantee of value.

Financials

Banks and insurers often trade at lower P/E and P/B multiples than the broad market, partly because earnings are cyclical and sensitive to interest rates and credit. P/B is the more telling measure here.

• Wells Fargo (WFC). A large US bank whose valuation has often sat below the market on P/E and near book value, a pattern typical of the sector. Whether that reflects genuine value or the risks banks carry is exactly what research has to decide.
• Citigroup (C). A global bank that has frequently traded below its book value, a classic low-P/B screening hit, and a reminder that a discount to book can persist for years if returns stay low.
• Bank of America (BAC). A money-center bank whose multiple tracks the rate cycle, illustrating how cyclical earnings make a single P/E reading hard to interpret without context.

Energy

Energy majors tend to carry low P/E and EV/EBITDA multiples because earnings swing with commodity prices and the market discounts the long-term transition away from fossil fuels. Free-cash-flow yield is often the focus.

• Chevron (CVX). An integrated oil major that has often traded at a modest multiple with a high free-cash-flow yield, the energy-sector pattern, alongside the cyclicality and transition risk that explain why the multiple is low.
• ExxonMobil (XOM). The largest US oil company, a frequent low-EV/EBITDA screening example whose valuation rises and falls with oil prices rather than with any company-specific change.
• ConocoPhillips (COP). An exploration-and-production name whose multiple is tightly tied to commodity prices, a good illustration of why a cheap energy stock can stay cheap if prices fall.

Healthcare

Several large pharma and managed-care names trade below the broad market on P/E, reflecting patent-cliff worries, pipeline uncertainty, and policy risk. The caveat is that a cheap multiple here can signal a real earnings threat.

• Pfizer (PFE). A large pharma company whose P/E has often sat below the market amid concerns about declining post-pandemic revenue and patent expirations, a textbook case of cheap-but-why.
• CVS Health (CVS). A healthcare and pharmacy-benefits company that has traded at a low P/E, where the question is whether the discount reflects temporary pressure or a structural one.
• Bristol Myers Squibb (BMY). A large pharma name often screening cheap on forward P/E because of looming patent cliffs, a clear example of why forward estimates matter more than the trailing number.

A list of cheap-looking stocks is an input, not a portfolio. Even when your research says a name is genuinely undervalued, concentration risk is real: any single thesis can be wrong. The repeatable way to act on value ideas without betting everything on one looks like this.

• Spread across the value candidates you trust. A handful of names across different sectors (a bank, an energy major, a healthcare name) diversifies the risk that any one is a value trap.
• Set target weights. Give each position a deliberate weight summing to 100, so no single value idea dominates if it goes wrong.
• Compare against the S&P 500. A value tilt should earn its keep versus simply holding the index, so check how the mix would have tracked the benchmark.
• Revisit the thesis. Value plays out over time, so review periodically and ask whether the reason you thought a name was cheap still holds.

This is what Walnut is built for. You create a thematic basket from the stocks you choose, set a target weight for each, see how the basket would track against the S&P 500, and place trades you approve yourself at your own broker. You can also talk through a company’s valuation with an AI assistant before you decide. Walnut does not tell you which stocks are undervalued or which to buy.

An undervalued stock is one trading below a reasonable estimate of its worth, measured either by intrinsic value from a DCF or by multiples relative to peers and history. Finding one means screening on metrics like P/E, P/B, PEG, EV/EBITDA, and free-cash-flow yield, then doing the qualitative work to make sure the stock is genuinely mispriced rather than a value trap that is cheap for a reason. Cheaper multiples cluster in sectors the market is cautious on, such as financials, energy, and healthcare, but a low sector multiple still demands company-by-company research. The honest framing is that “undervalued” is always a judgment, so treat every metric as a prompt and every named company as a starting point. Walnut helps you turn your own research into a thematic basket you control. It is not an investment adviser, and nothing here is a recommendation.